OncoHost Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
46
- Latest Deal Type
-
2ndary - Private
- Investors
-
8
OncoHost General Information
Description
Developer of personalized precision diagnostics and AI-based technology designed to maximize the success of cancer therapy. The company combines bioinformatics, system biology, proteomic pattern recognition, and machine learning to assign a score, a measure of the predicted clinical benefit from PD-1/PD-L1 inhibitors correlated to the patient's overall survival, and list clinical evidence-based treatment considerations, enabling healthcare institutions to identify patients' non-responsiveness to cancer treatments and help them discover new targets to overcome treatment resistance.
Contact Information
Website
www.oncohost.comCorporate Office
- 1110 SouthEast Cary Parkway
- Suite 205
- Cary, NC 27518
- United States
Corporate Office
- 1110 SouthEast Cary Parkway
- Suite 205
- Cary, NC 27518
- United States
OncoHost Timeline
OncoHost Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Secondary Transaction - Private | 01-Oct-2025 | Completed | Generating Revenue | |||
| 8. Grant | 15-May-2025 | Completed | Generating Revenue | |||
| 7. Later Stage VC | 01-Mar-2024 | Completed | Generating Revenue | |||
| 6. Equity Crowdfunding | Cancelled | Startup | ||||
| 5. Later Stage VC (Series C) | 10-May-2022 | Completed | Startup | |||
| 4. Early Stage VC (Series B) | 01-Sep-2020 | Completed | Startup | |||
| 3. Grant | 01-Jan-2020 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 01-May-2019 | $5M | $6.55M | Completed | Startup | |
| 1. Seed Round | 01-Oct-2017 | $1.55M | $1.55M | Completed | Startup |
OncoHost Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preferred C Share | ||||||||
| Preferred B-1 Shares | ||||||||
| Preferred B Shares | ||||||||
| Preferred A Shares | 242,022 | $0.010000 | $22.9 | $22.9 | 1x | $22.9 | 13.47% | |
| Preferred Seed Share | 77,487 | $0.010000 | $20 | $20 | 1x | $20 | 5.5% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
OncoHost Comparisons
Industry
Financing
Details
OncoHost Competitors (7)
One of OncoHost’s 7 competitors is BostonGene, a Venture Capital-Backed company based in Waltham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BostonGene | Venture Capital-Backed | Waltham, MA | ||||
| InterVenn Biosciences | Venture Capital-Backed | South San Francisco, CA | ||||
| Foundation Medicine | Formerly VC-backed | Boston, MA | ||||
| Veracyte | Formerly VC-backed | South San Francisco, CA | ||||
| Guardant Health | Formerly VC-backed | Palo Alto, CA |
OncoHost Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
OncoHost Patents
OncoHost Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026053217-A1 | A system and method for predicting probability of clinical benefit of a treatment in a patient | Pending | 05-Sep-2024 | ||
| WO-2025233947-A1 | Predicting patient response | Pending | 09-May-2024 | ||
| AU-2024372644-A1 | Predicting anti-cancer therapy related adverse event | Pending | 31-Oct-2023 | ||
| EP-4802280-A1 | Predicting anti-cancer therapy related adverse event | Pending | 31-Oct-2023 | ||
| WO-2025094183-A1 | Predicting anti-cancer therapy related adverse event | Inactive | 31-Oct-2023 | G16H10/40 |
OncoHost Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
OncoHost Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| European Innovation Council | Accelerator/Incubator | |||
| ALIVE Israel Healthtech Fund | Venture Capital | Minority | ||
| Katao Venture Partners | Venture Capital | Minority | ||
| Leumi Partners | PE/Buyout | Minority | ||
| Menora Mivtachim Holdings | Corporation | Minority |
OncoHost FAQs
-
When was OncoHost founded?
OncoHost was founded in 2017.
-
Where is OncoHost headquartered?
OncoHost is headquartered in Cary, NC.
-
What is the size of OncoHost?
OncoHost has 46 total employees.
-
What industry is OncoHost in?
OncoHost’s primary industry is Decision/Risk Analysis.
-
Is OncoHost a private or public company?
OncoHost is a Private company.
-
What is OncoHost’s current revenue?
The current revenue for OncoHost is .
-
How much funding has OncoHost raised over time?
OncoHost has raised $50.1M.
-
Who are OncoHost’s investors?
European Innovation Council, ALIVE Israel Healthtech Fund, Katao Venture Partners, Leumi Partners, and Menora Mivtachim Holdings are 5 of 8 investors who have invested in OncoHost.
-
Who are OncoHost’s competitors?
BostonGene, InterVenn Biosciences, Foundation Medicine, Veracyte, and Guardant Health are some of the 7 competitors of OncoHost.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
